So, what To Expect From LGK-974?

Safety and efficacy were explored overall and in subgroups of patients including those with no prior therapy, nonclear cell (nonclear cell) RCC, brain metastases, prior bevacizumab treatment, and elderly patients. Sorafenib was approved for RCC 6 months after study initiation, at which time patients with no prior therapy or with nonclear cell RCC could enroll in an extension protocol for continued assessment for a period of 6 months. The most common grade ��2 drug-related adverse events were hand-foot skin reaction (18%), rash (14%), hypertension (12%), and fatigue (11%). http://www.selleck.cn/products/VX-809.html In the 1891 patients evaluable for response, complete response was observed in 1 patient, partial response in 67 patients (4%), and stable disease for at least 8 weeks in 1511 patients (80%). Median progression-free survival in the extension population was 36 weeks (95% confidence interval [CI], 33-45 weeks; censorship rate, 56%); median overall survival in the entire population was 50 weeks (95% CI, 46-52 weeks; censorship rate, 63%). The efficacy and safety results were similar across the subgroups. Sorafenib 400 mg twice daily demonstrated activity and a clinically acceptable toxicity profile in all patient subsets enrolled in the http://www.selleckchem.com/products/17-AAG(Geldanamycin).html ARCCS expanded access program (clinicaltrials.gov identifier: NCT00111020). Cancer 2010. ? 2010 American Cancer Society. In 2008, 54,390 new cases of cancer of the kidney or renal pelvis were estimated to be diagnosed in the United States, with approximately 90% classified as renal cell carcinoma (RCC), and 13,010 patients were estimated to die of the disease.1, 2 The traditional 5-year survival rate for patients with metastatic RCC is estimated to be http://www.selleckchem.com/products/lgk-974.html limited efficacy and are associated with significant toxicity.6-12 Recognition of the essential role of VEGF in RCC pathogenesis led to the testing of angiogenesis inhibitors in this disease.13 Sorafenib is a potent multikinase inhibitor of receptor tyrosine kinases VEGF receptors 1, 2, and 3 and platelet-derived growth factor receptors �� and ��, as well as the Raf/MEK/ERK pathway at the level of Raf kinase.14 In xenograft models, sorafenib administered as a single agent had potent antiangiogenic activity and was found to inhibit the growth of RCC tumors.15, 16 Sorafenib was investigated as monotherapy in 4 phase 1 trials17-20 and had an acceptable toxicity profile.